Antimitotic Agents: all 5,052 studies that test it

Page 2 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.

• WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLCRecruitingNCT07330050Phase 2
• Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBCRecruitingNCT07322263Phase 2
• CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerRecruitingNCT07322094Phase 1/2
• Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerRecruitingNCT07320586Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Phase 1
• Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate AdenocarcinomaRecruitingNCT07316686Phase 1
• A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.Not yet recruitingNCT07307443Phase 2
• Nelmastobart in Combination With Docetaxel in Non Small Cell Lung CancerRecruitingNCT07306624Phase 2
• A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingNCT07304258Phase 2
• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2
• Colchicine's Effect on Inflammatory MarkersRecruitingNCT07287345Phase 4
• Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)RecruitingNCT07283692Phase 2
• RECLAIM Adaptive Platform Trial for PCC TreatmentsEnrolling by invitationNCT07280572Phase 3
• Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadNot yet recruitingNCT07273656Phase 3
• Losartan and Paclitaxel in Platinum Resistant Ovarian CancerNot yet recruitingNCT07265739Phase 2
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07259317Phase 2
• BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationNCT07258680Phase 3
• Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingNCT07255612Phase 2
• Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic AdenocarcinomaRecruitingNCT07253662Phase 1
• The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade InflammationRecruitingNCT07247734Phase 2
• Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingNCT07246863Phase 2
• Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerRecruitingNCT07233252Phase 2
• PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosisRecruitingNCT07232069Phase 3
• ALL Backbone in AYAsRecruitingNCT07227584Phase 2
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2
• A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerRecruitingNCT07226427Phase 1
• PDT For Induction Therapy For Head And Neck CancerRecruitingNCT07214987Phase 2
• A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingNCT07205185Phase 2
• A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Not yet recruitingNCT07200947Phase 2
• A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic CancerRecruitingNCT07198659Early Phase 1
• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 2
• Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingNCT07194044Phase 1
• Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsRecruitingNCT07168980Phase 2/3
• Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07163273Phase 2
• Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
• Short-Term Outcomes of Early Administration of Colchicine in Non-ST Segment Elevation Myocardial Infarction Patients Treated With Drug-Eluting Stents.RecruitingNCT07143136Early Phase 1
• An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal RecurrenceEnrolling by invitationNCT07139951Phase 2
• Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in ChildrenNot yet recruitingNCT07137884Phase 2
• SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLCRecruitingNCT07131319Phase 2/3
• Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCRecruitingNCT07126119Phase 2
• Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral CancerRecruitingNCT07125547Phase 2
• Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT TrialRecruitingNCT07121595Phase 2
• HB1801 Combined Treatment of HER2-positive Breast CancerNot yet recruitingNCT07116824Phase 2
• A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingNCT07108270Phase 2
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2
• Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer PatientsRecruitingNCT07096869Phase 1
• Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07096362Phase 2
• Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Not applicable
• A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast CancerNot yet recruitingNCT07083505Phase 2
• Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaRecruitingNCT07076212Phase 2
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingNCT07069712Phase 2
• Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck CancerRecruitingNCT07065630Phase 2
• Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS PatientsRecruitingNCT07064109Not applicable
• Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT07057427Phase 3
• Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingNCT07044349Phase 2
• 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDACRecruitingNCT07043270Phase 2
• Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)Not yet recruitingNCT07035405Phase 3
• Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal CarcinomatosisRecruitingNCT07030283Phase 1
• PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingNCT07028424Phase 2
• Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral HemorrhageRecruitingNCT07026994Phase 2
• Personalised Timing of Interval Debulking Surgery in Advanced Ovarian CancerRecruitingNCT07022535Phase 2
• Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC PatientsNot yet recruitingNCT07021261Phase 3
• Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Phase 2
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerRecruitingNCT07017673Phase 2
• Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentRecruitingNCT07010692Phase 1/2
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)RecruitingNCT06992882Phase 3
• Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingNCT06984146Phase 2
• Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
• The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ ECNot yet recruitingNCT06965829Phase 2
• DT2216 + Paclitaxel in Platinum-Resistant Ovarian CancerRecruitingNCT06964009Phase 1
• Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingNCT06957431Phase 1
• Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)RecruitingNCT06954805Phase 2
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingNCT06949761Phase 1/2
• Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsRecruitingNCT06947291Phase 2
• AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
• Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical CancerRecruitingNCT06942416Phase 2
• Perioperative Colchicine for TKANot yet recruitingNCT06936709Phase 4
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialRecruitingNCT06931340Phase 3
• Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular DiseaseRecruitingNCT06930885Phase 3
• Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2
• A Study of QLM2011 in Subjects With Advanced Solid TumorsNot yet recruitingNCT06925659Phase 1
• Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ CancerNot yet recruitingNCT06904300Phase 2
• Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingNCT06897644Phase 3
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
• A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate CancerNot yet recruitingNCT06890832Phase 2
• Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
• Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type AdenocarcinomaNot yet recruitingNCT06870565Phase 3
• A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
• Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Phase 2
• Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.Not yet recruitingNCT06857747Not applicable
• Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.RecruitingNCT06856213Phase 2
• Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease TreatmentRecruitingNCT06855433Phase 2
• Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2

← Antimitotic Agents overview